Cosmo Pharmaceuticals N.V (C43) - Total Liabilities

Latest as of December 2025: €123.46 Million EUR ≈ $144.34 Million USD

Based on the latest financial reports, Cosmo Pharmaceuticals N.V (C43) has total liabilities worth €123.46 Million EUR (≈ $144.34 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Cosmo Pharmaceuticals N.V cash flow conversion to assess how effectively this company generates cash.

Cosmo Pharmaceuticals N.V - Total Liabilities Trend (2016–2025)

This chart illustrates how Cosmo Pharmaceuticals N.V's total liabilities have evolved over time, based on quarterly financial data. Check Cosmo Pharmaceuticals N.V (C43) asset resilience to evaluate the company's liquid asset resilience ratio.

Cosmo Pharmaceuticals N.V Competitors by Total Liabilities

The table below lists competitors of Cosmo Pharmaceuticals N.V ranked by their total liabilities.

Company	Country	Total Liabilities
Sobha Limited NSE:SOBHA	India	Rs140.36 Billion
S&T Bancorp Inc NASDAQ:STBA	USA	$8.41 Billion
PT Arkora Hydro Tbk JK:ARKO	Indonesia	Rp1.09 Trillion
Eco World Develop Group KLSE:8206	Malaysia	RM7.37 Billion
Almonty Industries Inc. Common Shares NASDAQ:ALM	USA	$261.80 Million
Anupam Rasayan India Limited NSE:ANURAS	India	Rs22.01 Billion
Greif Bros Corporation NYSE:GEF	USA	$2.43 Billion
PLUXEE NV PA:PLX	France	€5.93 Billion

Liability Composition Analysis (2016–2025)

This chart breaks down Cosmo Pharmaceuticals N.V's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Cosmo Pharmaceuticals N.V (C43) market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	7.18	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.26	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.20	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Cosmo Pharmaceuticals N.V's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Cosmo Pharmaceuticals N.V (2016–2025)

The table below shows the annual total liabilities of Cosmo Pharmaceuticals N.V from 2016 to 2025.

Year	Total Liabilities	Change
2025-12-31	€123.46 Million ≈ $144.34 Million	-12.86%
2024-12-31	€141.68 Million ≈ $165.64 Million	+15.73%
2023-12-31	€122.42 Million ≈ $143.12 Million	-58.61%
2022-12-31	€295.80 Million ≈ $345.83 Million	+1.00%
2021-12-31	€292.88 Million ≈ $342.41 Million	+49.40%
2020-12-31	€196.04 Million ≈ $229.19 Million	+2.41%
2019-12-31	€191.43 Million ≈ $223.80 Million	+5.86%
2018-12-31	€180.83 Million ≈ $211.41 Million	+549.14%
2017-12-31	€27.86 Million ≈ $32.57 Million	-0.21%
2016-12-31	€27.92 Million ≈ $32.64 Million	--

About Cosmo Pharmaceuticals N.V

F:C43 Germany Drug Manufacturers - General

Market Cap

$1.77 Billion

€1.52 Billion EUR

Market Cap Rank

#6973 Global

#992 in Germany

Share Price

€88.60

Change (1 day)

-1.45%

52-Week Range

€51.00 - €139.00

All Time High

€153.25